Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Endo USA Inc., a Keenova Therapeutics Company
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04681027CT.gov Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children | — | Suspended | — | — | — |
NCT01206907CT.gov Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects | — | Withdrawn | — | — | — |
NCT00930943CT.gov Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning | — | Completed | — | — | — |
NCT00765856CT.gov Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects | — | Terminated | — | — | — |
NCT00225797CT.gov Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain | — | Completed | — | — | — |
NCT00226421CT.gov Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain | — | Completed | — | — | — |
NCT00911261CT.gov Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Pain Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oxymorphone Cii (this asset) | Endo USA Inc., a Keenova Therapeutics Company | Approved | B · 62 |
| (±)-Tramadol | EMS | P4 | BBB |
| Methadone | Cari Health Inc. | P4 | BBB |
| Lidocaine | National and Kapodistrian University of Athens | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Stanford University | P4 | BBB |
| Nepenthe | Bursa City Hospital | P4 | BBB |
| Fentanyl | Aga Khan University | P4 | BBB |
| Oxycodone | Mayo Clinic | P4 | BBB |
| Pregabalin | Federico II University | P4 | BBB |
+42 more in the Chronic Pain Syndrome cohort
Other indications for Oxymorphone Cii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Disease | — | P3 | B · 57 |
| Opioid Abuse | — | P4 | B · 57 |
| Opiate Dependence | — | P4 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Oxymorphone Cii in Chronic Pain Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/oxymorphone-cii-chronic-pain-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →